Sharechat Logo

Pacific Edge launches second bladder test in NZ, flags US launch next year

Monday 8th December 2014

Text too small?

Pacific Edge, the non-invasive bladder cancer test developer, has launched its second cancer test in New Zealand and flags a US launch early next year.

The Dunedin based company launched Cxbladder Triage in New Zealand, its second commercialised cancer diagnostic test which sits alongside its first product, Cxbladder Detect, it said in a statement. The product seeks to screen the majority of patients to potentially avoid more intensive testing and care.

Pacific Edge will launch Triage in the US early next year, and will undertake a 2,000 patient evaluation at the Southern California Permanente Medical Group, which is part of the Kaiser Permanente, one of the largest healthcare providers in the US, it said.

The company aims to develop a range of products to meet the specific needs for the detection and management of bladder cancer, growing annual revenue to $100 million in the coming years. Much of that growth is expected to come from the US, with its non-invasive bladder cancer test, Cxbladder Detect, where it is securing healthcare provider trials. In New Zealand it provides the test through district health boards.

“The launch of Cxbladder Triage takes us a step closer to our vision of a ‘one stop shop’ for bladder cancer detection and management,” said chief executive David Darling. “Cxbladder Triage is the first of its kind in this market, combining known bladder cancer risk factors with molecular diagnostics to rule out bladder cancer with confidence.”

Last month, Pacific Edge said the European Patent Office granted a patent for the company's colorectal cancer prognostic technology, which is in the late stages of development and has already been patented in Japan.

Shares of Pacific Edge rose 3.5 percent to 88 cents, and have halved from their February peak of $1.76.


Bond Offer: Infratil Ltd, 7.2 year & 10.2 year unsecured unsubordinated bond

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

NZ dollar mixed, buffeted by Fed talk and downunder data
Super Fund can expect lower returns over next decade - review
ANALYSIS: Should penalties for continuous disclosure breaches be relaxed?
Fletcher seeks urgent talks on Ihumatao stalemate
NZ economy grows 0.5% in June quarter, beating expectations
Restaurant Brands lifts 2Q sales; appetite for KFC offsets ditched Starbucks
Auckland jet fuel arrangements a potential barrier to new entrants
NZ dollar weaker after Fed split on outlook for further US cuts
Leading judge says court administration model 'outdated'
MARKET CLOSE: NZ shares fall; Goodman placement sees property stocks sold

IRG See IRG research reports